Nubeqa (Darolutamide) is an androgen receptor inhibitor used to treat patients with non-metastatic castration-resistant prostate cancer.
Dosage: The recommended dose of darolutamide is 600 mg (2 × 300 mg film-coated tablets) administered orally, twice daily, equivalent to a total daily dose of 1200 mg. Swallow tablets whole with food. Patients with nubeqa dosage should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had a bilateral orchiectomy. Patients are advised to take any missed dose immediately as they remember before the next scheduled dose, and not to take a couple of doses together to make up for a missed dose.
Side Effects: The most commonly reported darolutamide side effects include:
- Pain in extremity
- Decreased white blood cells (neutropenia)
- Changes in liver function tests
Warnings and Precautions:
- Do not start or stop any medication before you talk with the healthcare provider that prescribed the nubeqa 300 mg tablet.
- Patients are advised that darolutamide may be hazardous to a developing fetus and may cause loss of pregnancy.
- Male patients with female partners of reproductive potential are advised to use apt contraception during therapy and for 7 days after the last dose of darolutamide 300 mg tablets.
- Darolutamide can cause fertility problems in males, which may affect the ability to father children. Talk to your health specialist in case you have concerns about fertility.